PACB

Business Context and Reporting Period

Pacific Biosciences of California, Inc. (PacBio) is a life science technology company developing advanced sequencing solutions, including HiFi long-read and Sequencing by Binding (SBB) short-read technologies. This summary covers the unaudited quarterly results for the period ended June 30, 2024 (Q2 2024).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 24% year-over-year in Q2 and 13% year-over-year for the six months ended June 30, 2024. This was primarily driven by a 51% drop in instrument revenue (24 Revio systems sold in Q2 2024 vs. 45 in Q2 2023), partially offset by a 24% increase in consumable revenue.
• Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $93.2 million in Q2 2024. This was triggered by a sustained decrease in stock price and market capitalization, alongside longer-than-expected sales cycles.
• Restructuring Charges: The company initiated expense reduction initiatives, incurring $18.0 million in restructuring charges in Q2 2024. This included $10.1 million in employee separation costs and $7.9 million in other costs (including accelerated amortization for the San Diego office closure and excess inventory charges).
• Operating Expenses: Total operating expenses increased significantly due to the goodwill impairment and restructuring charges, despite a 17% reduction in Research and Development (R&D) expenses driven by workforce reductions.

Guidance, Outlook, and Risks

• Expense Reduction: Management plans to reduce annualized run-rate operating expenses by the end of 2024 through workforce reductions, facility downsizing (closing San Diego office by September 2024), and refining the development pipeline. An additional $8.3 million in restructuring costs is expected to be incurred in the remainder of 2024.
• Sales Cycle Challenges: The median sales cycle for Revio instruments remains longer than expected due to funding uncertainty (particularly in the U.S. and China), procurement delays, and slower sample volume ramp-up by new customers.
• Liquidity: The company holds $509.8 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations beyond the next 12 months, though the company expects to continue incurring operating losses.
• Legal Proceedings: Significant patent litigation continues with Personal Genomics of Taiwan (PGI) and Take2 Technologies. While some claims have been stayed pending inter partes reviews, the outcomes remain uncertain and could impact operations.
• Geopolitical Risks: The company faces risks related to U.S.-China trade tensions, export controls on semiconductors, and supply chain dependencies on Taiwan for consumable chips.

Investor Verification Checklist

• Verify the sustainability of the $93.2 million goodwill impairment and assess if further impairments are likely given the current stock price and market capitalization.
• Monitor the execution of the expense reduction plan and the timeline for realizing the targeted reduction in annualized run-rate operating expenses.
• Track the Revio instrument sales cycle and the rate of transition from Sequel II/IIe to Revio consumables to gauge revenue recovery potential.
• Review the status of patent litigation (PGI and Take2) and the potential for injunctions or damages that could disrupt sales.
• Assess the impact of geopolitical tensions on the supply chain, specifically regarding semiconductor components sourced from or manufactured in China and Taiwan.